Overview

Pyronaridine Artesunate (3:1) Versus Coartem® in P Falciparum Malaria Patients

Status:
Completed
Trial end date:
2008-05-01
Target enrollment:
Participant gender:
Summary
The primary objective of this phase III study is to compare the efficacy and safety of the fixed combination of pyronaridine artesunate (Pyramax®, PA) with that of Coartem® (artemether lumefantrine, AL) in children and adults with uncomplicated P falciparum malaria in Africa and South East Asia.
Phase:
Phase 3
Details
Lead Sponsor:
Medicines for Malaria Venture
Collaborator:
Shin Poong Pharmaceuticals
Treatments:
Artemether
Artemether-lumefantrine combination
Artemether, Lumefantrine Drug Combination
Artemisinins
Artesunate
Lumefantrine
Pyronaridine